查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1842207

全球计算病理学市场：市场规模、份额、趋势分析（按组件、应用、技术、最终用途和地区划分）、细分市场预测（2025-2033 年）

Computational Pathology Market Size, Share & Trends Analysis Report By Component (Software, Services), By Application (Disease Diagnosis, Drug Discovery & Development), By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

计算病理学市场摘要

全球计算病理学市场预计在 2024 年达到 6.8248 亿美元，预计到 2033 年将达到 14.4762 亿美元，2025 年至 2033 年的复合年增长率为 9.0%。

成长的驱动因素包括机器学习和人工智慧 (AI) 技术的日益融合、对快速诊断的先进解决方案日益增长的需求、慢性病患病率的上升，以及专注于开发先进解决方案的市场参与企业对医疗保健领域不断增加的投资。

计算病理学市场的主要驱动力是慢性疾病（尤其是癌症）盛行率的不断上升。癌症的高发生率使得病理学家必须利用病理数据来为患者制定个人化治疗方案。因此，数位病理学越来越受到病理学家的青睐，因为它能够加快诊断速度、提高诊断准确性，并提供治疗提案以改善患者预后。例如，根据2023年8月发表在《病理学杂誌》（Journal of Pathology）上的一项研究，利用深度学习和人工智慧（AI）演算法分析和解读病理组织影像有望显着提高诊断准确性和效率，尤其是在癌症诊断和预后诊断。

将机器学习和人工智慧技术融入病理工作流程将显着改变诊断过程。例如，普鲁士于2024年10月推出了数位病理套件，旨在加速人工智慧模型的开发。这些工具使生命科学研究人员能够将切片检查切片影像转化为可用于训练底层模型、发现生物标记和改进诊断的定量数据。此类解决方案的开发能够实现影像的快速准确分析，帮助病理学家识别指示疾病进展的模式。透过自动化常规任务，人工智慧使病理学家能够专注于更复杂的诊断挑战，从而提高效率和准确性。这种转变将提高诊断准确性，并透过预测建模支持个人化医疗的发展。

目录

第一章 分析方法和范围

第二章执行摘要

第三章：计算病理学市场：驱动因素、趋势与范围

  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
  • 计算病理学市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL 分析
    • 科技趋势分析
    • 案例研究分析

第四章 计算病理学市场：按组件分類的估算和趋势分析

  • 按组件分類的市场份额（2024 年和 2033 年）
  • 细分仪表板
  • 全球计算病理学市场：未来展望（按组件划分）
  • 软体
  • 服务

第五章 计算病理学市场：按应用分類的估算和趋势分析

  • 按应用领域分類的市场份额（2024 年和 2033 年）
  • 细分仪表板
  • 全球计算病理学市场：未来展望（按应用领域划分）
  • 疾病诊断
  • 药物发现与开发
  • 学术研究

第六章：计算病理学市场：依技术分類的估算与趋势分析

  • 按技术分類的市场份额（2024 年和 2033 年）
  • 细分仪表板
  • 全球计算病理学市场：未来展望（按技术划分）
  • 机器学习（ML）
    • 深度学习
    • 受监督
    • 无人监管
    • 其他的
  • 自然语言处理（NLP）模型
  • 电脑视觉
  • 其他的

第七章 计算病理学市场：依最终用途分類的估算与趋势分析

  • 按最终用途分類的市场份额（2024 年和 2033 年）
  • 细分仪表板
  • 全球计算病理学市场：未来展望（按最终用途划分）
  • 医院、诊断实验室
  • 生物技术和製药公司
  • 学术研究机构
  • 其他的

第八章 计算病理学市场：区域估算和趋势分析（按组件、应用、技术和最终用途划分）

  • 按地区分類的市场份额分析（2024 年和 2033 年）
  • 市场概览：按地区
  • 全球市场概览：按地区划分
  • 市场规模预测及趋势分析（2021-2033）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争情势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 主要企业市占率/地位分析（2024 年）
  • 公司简介
    • Leica Biosystems Nussloch GmbH（subsidiary of Danaher）
    • Hamamatsu Photonics KK
    • Koninklijke Philips NV
    • Olympus Corporation
    • F. Hoffmann-La Roche Ltd.
    • Aiforia/Aiforia Technologies PLC
    • Epredia（3DHISTECH Ltd.）
    • Visiopharm A/S
    • Proscia Inc.
    • Mindpeak GmbH
    • Akoya Biosciences, Inc.（a Quanterix company）
    • Paige AI, Inc.
    • CellaVision
    • aetherAI
    • Qritive
    • IBEX（IBEX MEDICAL ANALYTICS）
    • Nucleai, Inc.
Product Code: GVR-4-68040-548-5

Computational Pathology Market Summary

The global computational pathology market size was estimated at USD 682.48 million in 2024 and is projected to reach USD 1,447.62 million by 2033, growing at a CAGR of 9.0% from 2025 to 2033. The growth is attributed to the rising integration of machine learning and artificial intelligence (AI) technologies, the increasing demand for advanced solutions for faster diagnosis, the rising prevalence of chronic diseases, and increasing investment in healthcare by market players focused on developing advanced solutions.

The computational pathology market is predominantly propelled by the increasing incidence of chronic diseases, notably cancer. The high prevalence of cancer necessitates pathologists to utilize pathology data that can aid in tailoring personalized therapies for patients. Thereby, digital pathology is increasingly being preferred by pathologists, as it accelerates the rate of diagnosis, increases diagnostic accuracy, and provides therapeutic recommendations to improve patient outcomes. For instance, according to a study published in the Journal of Pathology in August 2023, deep learning and artificial intelligence (AI) algorithms to analyze and interpret histopathology images promises substantial improvements in diagnostic accuracy and efficiency, especially for cancer diagnosis and prognosis.

The incorporation of machine learning and AI technologies into pathology workflows significantly transforms the diagnostic process. For instance, in October 2024, Proscia introduced digital pathology toolkits designed to facilitate the development of AI models. These tools enable life science researchers to convert biopsy slide images into quantitative data for training foundation models, improving biomarker discovery, and diagnostics. The development of such solutions enables the rapid and accurate analysis of images, allowing pathologists to identify patterns that may indicate disease progression. By automating routine tasks, AI enables pathologists to focus on more complex diagnostic challenges, thereby improving efficiency and accuracy. This shift enhances diagnostic precision and supports the development of personalized medicine through predictive modeling.

Global Computational Pathology Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global computational pathology market report based on component, application, technology, end use, and region:

  • Component Outlook (Revenue, USD Million, 2021 - 2033)
  • Software
  • Services
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Disease Diagnosis
  • Drug Discovery & Development
  • Academic Research
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Machine Learning (ML)
    • Deep Learning
    • Supervised
    • Unsupervised
    • Others
  • Natural Language Processing (NLP) Models
  • Computer Vision
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Diagnostic Labs
  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Institutes
  • Other
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional scope
    • 1.1.2. Component
    • 1.1.3. Technology
    • 1.1.4. Application
    • 1.1.5. End Use
    • 1.1.6. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Component
    • 2.2.2. Technology
    • 2.2.3. Application
    • 2.2.4. End Use
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Computational Pathology Market Variables, Trends & Scope

  • 3.1. Market Dynamics
    • 3.1.1. Market driver analysis
      • 3.1.1.1. Increasing prevalence of chronic diseases
      • 3.1.1.2. Higher cost-efficiency
      • 3.1.1.3. Rapid technological advancements in the computational pathology
      • 3.1.1.4. Emergence of Quantitative Continuous Scoring (QCS) in digital pathology
    • 3.1.2. Market restraint analysis
      • 3.1.2.1. Lack of reimbursement for computational pathology-enabled services
      • 3.1.2.2. Data security and privacy
    • 3.1.3. Market Opportunity Analysis
    • 3.1.4. Market Challenge Analysis
  • 3.2. Computational Pathology Market Analysis Tools
    • 3.2.1. Industry Analysis - Porter's
      • 3.2.1.1. Supplier power
      • 3.2.1.2. Buyer power
      • 3.2.1.3. Substitution threat
      • 3.2.1.4. Threat of new entrant
      • 3.2.1.5. Competitive rivalry
    • 3.2.2. PESTEL Analysis
      • 3.2.2.1. Political landscape
      • 3.2.2.2. Economic landscape
      • 3.2.2.3. Social landscape
      • 3.2.2.4. Technological landscape
      • 3.2.2.5. Environmental landscape
      • 3.2.2.6. Legal landscape
    • 3.2.3. Technology Trends Analysis
    • 3.2.4. Case Study Analysis

Chapter 4. Computational Pathology Market: Component Estimates & Trend Analysis

  • 4.1. Component Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Computational Pathology Market by Component Outlook
  • 4.4. Software
    • 4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 4.5. Services
    • 4.5.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Computational Pathology Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Computational Pathology Market by Application Outlook
  • 5.4. Disease Diagnosis
    • 5.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 5.5. Drug Discovery & Development
    • 5.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 5.6. Academic Research
    • 5.6.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Computational Pathology Market: Technology Estimates & Trend Analysis

  • 6.1. Technology Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Computational Pathology Market by Technology Outlook
  • 6.4. Machine Learning (ML)
    • 6.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
    • 6.4.2. Deep Learning
      • 6.4.2.1. Market estimates and forecast 2021 to 2033 (USD Million)
    • 6.4.3. Supervised
      • 6.4.3.1. Market estimates and forecast 2021 to 2033 (USD Million)
    • 6.4.4. Unsupervised
      • 6.4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
    • 6.4.5. Others
      • 6.4.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 6.5. Natural Language Processing (NLP) Models
    • 6.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 6.6. Computer Vision
    • 6.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. Computational Pathology Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global Computational Pathology Market by End Use Outlook
  • 7.4. Hospitals and Diagnostic Labs
    • 7.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 7.5. Biotechnology and Pharmaceutical Companies
    • 7.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 7.6. Academic and Research Institutes
    • 7.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 7.7. Others
    • 7.7.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 8. Computational Pathology Market: Regional Estimates & Trend Analysis, By Component, By Application, By Technology, By End Use

  • 8.1. Regional Market Share Analysis, 2024 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Singapore market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Key company market share/position analysis, 2024
  • 9.4. Company Profiles
    • 9.4.1. Leica Biosystems Nussloch GmbH (subsidiary of Danaher)
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Hamamatsu Photonics K.K.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Koninklijke Philips N.V.
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Olympus Corporation
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. F. Hoffmann-La Roche Ltd.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Aiforia/ Aiforia Technologies PLC
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Epredia (3DHISTECH Ltd.)
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Visiopharm A/S
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Proscia Inc.
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Mindpeak GmbH
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives
    • 9.4.11. Akoya Biosciences, Inc. (a Quanterix company)
      • 9.4.11.1. Company overview
      • 9.4.11.2. Financial performance
      • 9.4.11.3. Product benchmarking
      • 9.4.11.4. Strategic initiatives
    • 9.4.12. Paige AI, Inc.
      • 9.4.12.1. Company overview
      • 9.4.12.2. Financial performance
      • 9.4.12.3. Product benchmarking
      • 9.4.12.4. Strategic initiatives
    • 9.4.13. CellaVision
      • 9.4.13.1. Company overview
      • 9.4.13.2. Financial performance
      • 9.4.13.3. Product benchmarking
      • 9.4.13.4. Strategic initiatives
    • 9.4.14. aetherAI
      • 9.4.14.1. Company overview
      • 9.4.14.2. Financial performance
      • 9.4.14.3. Product benchmarking
      • 9.4.14.4. Strategic initiatives
    • 9.4.15. Qritive
      • 9.4.15.1. Company overview
      • 9.4.15.2. Financial performance
      • 9.4.15.3. Product benchmarking
      • 9.4.15.4. Strategic initiatives
    • 9.4.16. IBEX (IBEX MEDICAL ANALYTICS)
      • 9.4.16.1. Company overview
      • 9.4.16.2. Financial performance
      • 9.4.16.3. Product benchmarking
      • 9.4.16.4. Strategic initiatives
    • 9.4.17. Nucleai, Inc.
      • 9.4.17.1. Company overview
      • 9.4.17.2. Financial performance
      • 9.4.17.3. Product benchmarking
      • 9.4.17.4. Strategic initiatives

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Computational Pathology Market outlook
  • Fig. 9 Computational Pathology competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Computational Pathology Market driver impact
  • Fig. 15 Computational Pathology Market restraint impact
  • Fig. 16 Computational Pathology Market strategic initiatives analysis
  • Fig. 17 Computational Pathology Market: Component movement analysis
  • Fig. 18 Computational Pathology Market: Component outlook and key takeaways
  • Fig. 19 Software market estimates and forecast, 2021 - 2033
  • Fig. 20 Services market estimates and forecast, 2021 - 2033
  • Fig. 21 Computational Pathology Market: Application movement analysis
  • Fig. 22 Computational Pathology Market: Application outlook and key takeaways
  • Fig. 23 Disease diagnosis market estimates and forecast, 2021 - 2033
  • Fig. 24 Drug discovery & development market estimates and forecast, 2021 - 2033
  • Fig. 25 Academic research market estimates and forecast, 2021 - 2033
  • Fig. 26 Computational Pathology Market: Technology movement analysis
  • Fig. 27 Computational Pathology Market: Technology outlook and key takeaways
  • Fig. 28 Machine Learning (ML) market estimates and forecast, 2021 - 2033
  • Fig. 29 Deep Learning market estimates and forecast, 2021 - 2033
  • Fig. 30 Supervised market estimates and forecast, 2021 - 2033
  • Fig. 31 Unsupervised market estimates and forecast, 2021 - 2033
  • Fig. 32 Others market estimates and forecast, 2021 - 2033
  • Fig. 33 Natural Language Processing (NLP) models market estimates and forecast, 2021 - 2033
  • Fig. 34 Computer vision market estimates and forecast, 2021 - 2033
  • Fig. 35 Others market estimates and forecast, 2021 - 2033
  • Fig. 36 Computational Pathology Market: End use movement analysis
  • Fig. 37 Computational Pathology Market: End use outlook and key takeaways
  • Fig. 38 Hospitals and Diagnostic Labs market estimates and forecast, 2021 - 2033
  • Fig. 39 Biotechnology and Pharmaceutical Companies market estimates and forecast, 2021 - 2033
  • Fig. 40 Academic and Research Institutes market estimates and forecast, 2021 - 2033
  • Fig. 41 Other market estimates and forecast, 2021 - 2033
  • Fig. 42 Global Computational Pathology Market: Regional movement analysis
  • Fig. 43 Global Computational Pathology Market: Regional outlook and key takeaways
  • Fig. 44 Global Computational Pathology Market share and leading players
  • Fig. 45 North America market share and leading players
  • Fig. 46 Europe market share and leading players
  • Fig. 47 Asia Pacific market share and leading players
  • Fig. 48 Latin America market share and leading players
  • Fig. 49 Middle East & Africa market share and leading players
  • Fig. 50 North America market estimates and forecasts, 2021 - 2033
  • Fig. 51 U S market estimates and forecasts, 2021 - 2033
  • Fig. 52 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 53 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 54 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 55 UK market estimates and forecasts, 2021 - 2033
  • Fig. 56 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 57 France market estimates and forecasts, 2021 - 2033
  • Fig. 58 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 59 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 60 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 61 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 62 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 63 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 64 China market estimates and forecasts, 2021 - 2033
  • Fig. 65 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 66 India market estimates and forecasts, 2021 - 2033
  • Fig. 67 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 68 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 69 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 70 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 71 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 72 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 73 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 74 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 75 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 76 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 77 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 78 Market share of key market players- Computational Pathology Market
  • Fig. 79 Key Company Categorization
  • Fig. 80 Company Market Share/Position Analysis, 2024
  • Fig. 81 Strategic Framework
  • List of Fures
  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Computational Pathology Market outlook
  • Fig. 9 Computational Pathology competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Computational Pathology Market driver impact
  • Fig. 15 Computational Pathology Market restraint impact
  • Fig. 16 Computational Pathology Market strategic initiatives analysis
  • Fig. 17 Computational Pathology Market: Component movement analysis
  • Fig. 18 Computational Pathology Market: Component outlook and key takeaways
  • Fig. 19 Software market estimates and forecast, 2021 - 2033
  • Fig. 20 Services market estimates and forecast, 2021 - 2033
  • Fig. 21 Computational Pathology Market: Application movement analysis
  • Fig. 22 Computational Pathology Market: Application outlook and key takeaways
  • Fig. 23 Disease diagnosis market estimates and forecast, 2021 - 2033
  • Fig. 24 Drug discovery & development market estimates and forecast, 2021 - 2033
  • Fig. 25 Academic research market estimates and forecast, 2021 - 2033
  • Fig. 26 Computational Pathology Market: Technology movement analysis
  • Fig. 27 Computational Pathology Market: Technology outlook and key takeaways
  • Fig. 28 Machine Learning (ML) market estimates and forecast, 2021 - 2033
  • Fig. 29 Deep Learning market estimates and forecast, 2021 - 2033
  • Fig. 30 Supervised market estimates and forecast, 2021 - 2033
  • Fig. 31 Unsupervised market estimates and forecast, 2021 - 2033
  • Fig. 32 Others market estimates and forecast, 2021 - 2033
  • Fig. 33 Natural Language Processing (NLP) models market estimates and forecast, 2021 - 2033
  • Fig. 34 Computer vision market estimates and forecast, 2021 - 2033
  • Fig. 35 Others market estimates and forecast, 2021 - 2033
  • Fig. 36 Computational Pathology Market: End use movement analysis
  • Fig. 37 Computational Pathology Market: End use outlook and key takeaways
  • Fig. 38 Hospitals and Diagnostic Labs market estimates and forecast, 2021 - 2033
  • Fig. 39 Biotechnology and Pharmaceutical Companies market estimates and forecast, 2021 - 2033
  • Fig. 40 Academic and Research Institutes market estimates and forecast, 2021 - 2033
  • Fig. 41 Other market estimates and forecast, 2021 - 2033
  • Fig. 42 Global Computational Pathology Market: Regional movement analysis
  • Fig. 43 Global Computational Pathology Market: Regional outlook and key takeaways
  • Fig. 44 Global Computational Pathology Market share and leading players
  • Fig. 45 North America market share and leading players
  • Fig. 46 Europe market share and leading players
  • Fig. 47 Asia Pacific market share and leading players
  • Fig. 48 Latin America market share and leading players
  • Fig. 49 Middle East & Africa market share and leading players
  • Fig. 50 North America market estimates and forecasts, 2021 - 2033
  • Fig. 51 U S market estimates and forecasts, 2021 - 2033
  • Fig. 52 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 53 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 54 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 55 UK market estimates and forecasts, 2021 - 2033
  • Fig. 56 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 57 France market estimates and forecasts, 2021 - 2033
  • Fig. 58 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 59 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 60 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 61 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 62 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 63 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 64 China market estimates and forecasts, 2021 - 2033
  • Fig. 65 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 66 India market estimates and forecasts, 2021 - 2033
  • Fig. 67 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 68 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 69 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 70 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 71 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 72 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 73 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 74 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 75 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 76 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 77 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 78 Market share of key market players- Computational Pathology Market
  • Fig. 79 Key Company Categorization
  • Fig. 80 Company Market Share/Position Analysis, 2024
  • Fig. 81 Strategic Framework